Balaxi Pharma (BALAXI)

Score breakdown: P/E: 3/3 · ROCE: 1/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Trades at ₹27.50 versus book value of ₹45.56, a 40% discount to tangible equity
• Low debt-to-equity of 0.24, providing balance sheet stability
• ROCE of 12.95% indicates reasonable operating capital efficiency
• Promoter holding at 65.99% aligns management with minority shareholders
• Sales base relatively stable at ₹73 crore last quarter, with only -1.02% annual decline

Concerns

• Profit growth down 94.22%, and latest quarter net profit is ₹0 crore, signaling severe earnings erosion
• Piotroski F-score of 3/9 points to weak financial health and possible accounting stress
• Zero dividend yield provides no income support while waiting for recovery
• No apparent moat in a competitive small-cap pharma environment

AI Analysis

At first glance, Balaxi Pharma looks like a typical Graham cigar butt. The market cap is just ₹109 crore, while the book value per share is ₹45.56. Buying at ₹27.50 means you are paying only 60 paise for each rupee of equity. The balance sheet supports this view—debt-to-equity is a modest 0.24, and return on capital employed is 12.95%. But a value investor must separate a bargain from a value trap. The profit picture is alarming: profit growth has crashed by 94.22%, and the latest quarter shows sales of ₹73 crore but net profit of zero. A business that cannot convert revenue into earnings is not a compounding machine. The Piotroski F-score of 3/9 confirms deteriorating fundamentals—this is not a high-quality business. I also see no durable moat. It is a small pharmaceutical player in a highly competitive market, and the zero dividend yield means shareholders are not being paid to wait. With promoter holding at 65.99%, interests are aligned, but that alone is not enough. The assets are real, and low debt gives the company time. But time is not money if management cannot restore profitability. I would not call this a stalwart or a grower. It is an asset play—a stock trading at a steep discount to book with operational headwinds. I would only be interested at this price if I had high confidence that the zero-profit quarter is a one-off and not a new trend. As Graham said, price is what you pay, value is what you get. Here, the value depends entirely on whether earnings can be resurrected. Until I see a clear path to positive net profit, the margin of safety is real but thin.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer